Yeşim Eralp

2.1k total citations
94 papers, 1.3k citations indexed

About

Yeşim Eralp is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yeşim Eralp has authored 94 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 28 papers in Cancer Research and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yeşim Eralp's work include Breast Cancer Treatment Studies (19 papers), Ovarian cancer diagnosis and treatment (15 papers) and Cancer Treatment and Pharmacology (10 papers). Yeşim Eralp is often cited by papers focused on Breast Cancer Treatment Studies (19 papers), Ovarian cancer diagnosis and treatment (15 papers) and Cancer Treatment and Pharmacology (10 papers). Yeşim Eralp collaborates with scholars based in Türkiye, United States and Taiwan. Yeşim Eralp's co-authors include Erkan Topuz, Pınar Saip, Adnan Aydıner, Faruk Taş, Mert Başaran, Burak Sakar, Süleyman Alıcı, Hakan Çamlıca, Vahit Özmen and İrfan Çiçin and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Yeşim Eralp

88 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yeşim Eralp Türkiye 21 555 344 279 221 198 94 1.3k
Catherine Shannon Australia 20 704 1.3× 285 0.8× 286 1.0× 183 0.8× 191 1.0× 48 1.2k
Aránzazu Manzano Spain 16 571 1.0× 200 0.6× 308 1.1× 116 0.5× 216 1.1× 58 1.1k
Jurandyr Moreira de Andrade Brazil 21 690 1.2× 290 0.8× 158 0.6× 164 0.7× 157 0.8× 114 1.5k
George Zarkavelis Greece 15 458 0.8× 158 0.5× 170 0.6× 157 0.7× 126 0.6× 52 813
Amy Tiersten United States 20 1.0k 1.8× 275 0.8× 324 1.2× 96 0.4× 143 0.7× 101 1.6k
Victoria M. Chia United States 19 667 1.2× 212 0.6× 175 0.6× 204 0.9× 415 2.1× 36 1.6k
Furio Maggiorotto Italy 20 516 0.9× 534 1.6× 149 0.5× 322 1.5× 342 1.7× 44 1.3k
Aliza Leiser United States 13 335 0.6× 404 1.2× 228 0.8× 123 0.6× 112 0.6× 29 1.2k
Brenda Diergaarde United States 24 531 1.0× 371 1.1× 221 0.8× 234 1.1× 192 1.0× 68 1.5k
Sabrina Chiara Cecere Italy 20 615 1.1× 290 0.8× 200 0.7× 125 0.6× 227 1.1× 71 1.4k

Countries citing papers authored by Yeşim Eralp

Since Specialization
Citations

This map shows the geographic impact of Yeşim Eralp's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yeşim Eralp with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yeşim Eralp more than expected).

Fields of papers citing papers by Yeşim Eralp

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yeşim Eralp. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yeşim Eralp. The network helps show where Yeşim Eralp may publish in the future.

Co-authorship network of co-authors of Yeşim Eralp

This figure shows the co-authorship network connecting the top 25 collaborators of Yeşim Eralp. A scholar is included among the top collaborators of Yeşim Eralp based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yeşim Eralp. Yeşim Eralp is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Başaran, Gül, Erhan Gökmen, Nil Molinas Mandel, et al.. (2024). Artificial intelligence algorithms for recurrence risk score prediction in early-stage breast cancer: A multicenter study of 437 cases.. Journal of Clinical Oncology. 42(16_suppl). 545–545.
2.
Aksoy, Sercan, Burcu Çakar, Gül Başaran, et al.. (2023). Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group. Cancers. 15(6). 1667–1667. 1 indexed citations
3.
4.
Eralp, Yeşim & Utku Ateş. (2023). Clinical Applications of Combined Immunotherapy Approaches in Gastrointestinal Cancer: A Case-Based Review. Vaccines. 11(10). 1545–1545. 2 indexed citations
5.
6.
Smeltzer, Matthew, Giorgio V. Scagliotti, Heather A. Wakelee, et al.. (2022). International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials. Journal of Thoracic Oncology. 17(5). 651–660. 5 indexed citations
7.
Ordu, Çetın, Kezban Nur Pilancı, Gül Alço, et al.. (2018). Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes. SHILAP Revista de lepidopterología. 14(3). 173–179. 3 indexed citations
8.
Erdoğan, Zeynep, Çetın Ordu, Filiz Çelebi, et al.. (2017). Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.. PubMed. 21(6). 1425–1432. 13 indexed citations
9.
İlgün, Ahmet Serkan, Gül Alço, Çetın Ordu, et al.. (2017). Preoperative Lymphedema-Related Risk Factors in Early-Stage Breast Cancer. Lymphatic Research and Biology. 16(1). 28–35. 37 indexed citations
10.
Eralp, Yeşim. (2016). The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of Janus. PubMed Central. Suppl. 1. 1–7. 4 indexed citations
11.
Pilancı, Kezban Nur, Gül Alço, Çetın Ordu, et al.. (2015). Is Administration of Trastuzumab an Independent Risk Factor for Developing Osteonecrosis of the Jaw Among Metastatic Breast Cancer Patients Under Zoledronic Acid Treatment?. Medicine. 94(18). e671–e671. 18 indexed citations
12.
Gezer, Uğur, Serkan Keskın, Abdullah İğci, et al.. (2014). Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy. Oncology Letters. 8(2). 845–848. 20 indexed citations
13.
14.
Derin, Duygu, Yeşim Eralp, Yasemin Özlük, et al.. (2008). Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer. Cancer Investigation. 26(7). 671–679. 15 indexed citations
15.
Saip, Pınar, İrfan Çiçin, Yeşim Eralp, et al.. (2008). Factors affecting the prognosis of breast cancer patients with brain metastases. The Breast. 17(5). 451–458. 10 indexed citations
16.
Saip, Pınar, İrfan Çiçin, Yeşim Eralp, et al.. (2008). Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis. Journal of Neuro-Oncology. 93(2). 243–251. 14 indexed citations
17.
Eralp, Yeşim, Duygu Derin, Ekrem Yavuz, et al.. (2007). MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Annals of Oncology. 19(4). 669–674. 49 indexed citations
18.
Taş, Faruk, Zeki Üstüner, Gülbeyaz Can, et al.. (2005). The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients. Acta Oncologica. 44(2). 161–167. 66 indexed citations
19.
Gonzalez‐Angulo, Ana M., Kristine Broglio, Shu‐Wan Kau, et al.. (2005). Women age ≤ 35 years with primary breast carcinoma. Cancer. 103(12). 2466–2472. 70 indexed citations
20.
Eralp, Yeşim, Ahmet Dobrucalı, Alper Çelik, et al.. (2000). A comparison of lansoprazole and omeprazole based triple combinations for the treatment of Helicobacter pylori associated gastritis and peptic ulcer.. SHILAP Revista de lepidopterología. 11(1). 25–29. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Catherine Shannon Breakdown of academic impact, for papers by Aránzazu Manzano Breakdown of academic impact, for papers by Jurandyr Moreira de Andrade Breakdown of academic impact, for papers by George Zarkavelis Breakdown of academic impact, for papers by Amy Tiersten Breakdown of academic impact, for papers by Victoria M. Chia Breakdown of academic impact, for papers by Furio Maggiorotto Breakdown of academic impact, for papers by Aliza Leiser Breakdown of academic impact, for papers by Brenda Diergaarde Breakdown of academic impact, for papers by Sabrina Chiara Cecere
Rankless by CCL
2026